Searching for treatments for non-G12C-KRAS mutant cancers

被引：4

作者：

Guo, Christina ^{[1
,2
]}

Banerji, Udai ^{[1
,2
]}

机构：

[1] Inst Canc Res, London, England

[2] Royal Marsden Hosp NHS Fdn Trust, London, England

来源：

BRITISH JOURNAL OF CANCER | 2021年 / 125卷 / 05期

关键词：

DOSE-ESCALATION; MEK; INHIBITOR; SAFETY;

D O I：

10.1038/s41416-021-01357-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

KRAS mutations drive a wide variety of cancers. Drugs targeting the protein product of KRAS(G12C) mutations are currently being evaluated show preliminary efficacy in clinical trials. A clinical trial of VS-6766, a dual RAF-MEK inhibitor, has reported early single agent activity in non-G12C mutated KRAS driven cancers.

引用

页码：625 / 626

页数：2

共 50 条

[1] Searching for treatments for non-G12C-KRAS mutant cancers
Christina Guo
Udai Banerji
British Journal of Cancer, 2021, 125 : 625 - 626
[2] Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Janes, Matthew R.
Zhang, Jingchuan
Li, Lian-Sheng
Hansen, Rasmus
Peters, Ulf
Guo, Xin
Chen, Yuching
Babbar, Anjali
Firdaus, Sarah J.
Darjania, Levan
Feng, Jun
Chen, Jeffrey H.
Li, Shuangwei
Li, Shisheng
Long, Yun O.
Thach, Carol
Liu, Yuan
Zarieh, Ata
Ely, Tess
Kucharski, Jeff M.
Kessler, Linda V.
Wu, Tao
Yu, Ke
Wang, Yi
Yao, Yvonne
Deng, Xiaohu
Zarrinkar, Patrick P.
Brehmer, Dirk
Dhanak, Dashyant
Lorenzi, Matthew V.
Hu-Lowe, Dana
Patricelli, Matthew P.
Ren, Pingda
Liu, Yi
CELL, 2018, 172 (03) : 578 - +
[3] Targeting FAK to improve the therapy of KRAS G12C mutant cancers
Liu, Shuang
Shi, Junfen
Lu, Chang
Zhang, Miao
Xin, Ying
Zhu, Yan
Li, Jijun
Luo, Hong
Sun, Yinghui
CANCER RESEARCH, 2024, 84 (06)
[4] Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors
Rathod, Lala S.
Dabhade, Pratap S.
Mokale, Santosh N.
DRUG DISCOVERY TODAY, 2023, 28 (05) : 1 - 11
[5] Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers
O'Leary, Cian
Murphy, Grace
Yeung, Yong
Tang, Ming
Jain, Vikram
O'Leary, Connor G.
CANCERS, 2023, 15 (23)
[6] Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers
Khan, Husain Yar
Nagasaka, Misako
Li, Yiwei
Aboukameel, Amro
Uddin, Md. Hafiz
Sexton, Rachel
Bannoura, Sahar
Mzannar, Yousef
Al-Hallak, Mohammed Najeeb
Kim, Steve
Beydoun, Rafic
Landesman, Yosef
Mamdani, Hirva
Uprety, Dipesh
Philip, Philip A.
Mohammad, Ramzi M.
Shields, Anthony F.
Azmi, Asfar S.
CANCER RESEARCH COMMUNICATIONS, 2022, 2 (05): : 342 - 352
[7] Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257, a novel KRAS G12C mutant selective small molecule inhibitor
Christensen, James G.
Fell, Jay B.
Marx, Matthew A.
Fischer, John
Hallin, Jill
Calinisan, Andrew
Baer, Brian
Burkhard, Michael
Blake, James
Vigers, Guy
Aranda, Ruth
Hargis, Lauren
Briere, David
Engstrom, Lars
Olson, Peter
CANCER RESEARCH, 2019, 79 (13)
[8] Adaptive resistance to KRAS-G12C inhibitors through AXL activation in KRAS-G12C mutant tumor cells
Morimoto, Kenji
Yamada, Tadaaki
Hirai, Soichi
Katayama, Yuki
Yano, Seiji
Horinaka, Mano
Sakai, Toshiyuki
Tokuda, Shinsaku
Takayama, Koichi
CANCER SCIENCE, 2024, 115 : 111 - 111
[9] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
Adachi, Yuta
Ito, Kentaro
Kimura, Ryo
Yamaguchi, Rui
Ebi, Hiromichi
ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
[10] AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
Morimoto, Kenji
Yamada, Tadaaki
Hirai, Soichi
Katayama, Yuki
Fukui, Sarina
Sawada, Ryo
Tachibana, Yusuke
Matsui, Yohei
Nakamura, Ryota
Ishida, Masaki
Kawachi, Hayato
Kunimasa, Kei
Sasaki, Takaaki
Nishida, Makoto
Furuya, Naoki
Watanabe, Satoshi
Shiotsu, Shinsuke
Nishioka, Naoya
Horinaka, Mano
Sakai, Toshiyuki
Uehara, Hisanori
Yano, Seiji
Son, Bo-Kyung
Tokuda, Shinsaku
Takayama, Koichi
CANCER LETTERS, 2024, 587

← 1 2 3 4 5 →